Health Related Quality of Life in LCIG Patients and LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy. A Multicenter Post Marketing Observational Study for LCIG in Germany and Switzerland - BALANCE

Trial Profile

Health Related Quality of Life in LCIG Patients and LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy. A Multicenter Post Marketing Observational Study for LCIG in Germany and Switzerland - BALANCE

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms BALANCE
  • Sponsors AbbVie
  • Most Recent Events

    • 02 Jun 2017 Planned number of patients changed from 250 to 266.
    • 02 Jun 2017 Planned End Date changed from 1 Feb 2018 to 16 Dec 2018.
    • 02 Jun 2017 Planned primary completion date changed from 1 Feb 2018 to 16 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top